BRPI0919065A2 - anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite c - Google Patents
anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite cInfo
- Publication number
- BRPI0919065A2 BRPI0919065A2 BRPI0919065A BRPI0919065A BRPI0919065A2 BR PI0919065 A2 BRPI0919065 A2 BR PI0919065A2 BR PI0919065 A BRPI0919065 A BR PI0919065A BR PI0919065 A BRPI0919065 A BR PI0919065A BR PI0919065 A2 BRPI0919065 A2 BR PI0919065A2
- Authority
- BR
- Brazil
- Prior art keywords
- claudin
- monoclonal antibodies
- virus infection
- inhibiting hepatitis
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305597 | 2008-09-25 | ||
| EP08305597.0 | 2008-09-25 | ||
| PCT/EP2009/062449 WO2010034812A1 (en) | 2008-09-25 | 2009-09-25 | Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0919065A2 true BRPI0919065A2 (pt) | 2015-12-15 |
| BRPI0919065B1 BRPI0919065B1 (pt) | 2021-09-21 |
Family
ID=40352777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919065-1A BRPI0919065B1 (pt) | 2008-09-25 | 2009-09-25 | Anticorpos monoclonais anti-claudin-i para a inibição de infecção por vírus de hepatite c |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8518408B2 (pt) |
| EP (1) | EP2328933B1 (pt) |
| JP (1) | JP5698137B2 (pt) |
| KR (1) | KR101698015B1 (pt) |
| CN (1) | CN102224171B (pt) |
| BR (1) | BRPI0919065B1 (pt) |
| CA (1) | CA2738027C (pt) |
| ES (1) | ES2529511T3 (pt) |
| WO (1) | WO2010034812A1 (pt) |
| ZA (1) | ZA201102112B (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007248493B2 (en) | 2006-05-04 | 2010-09-30 | The Rockefeller University | HCV coreceptor and methods of use thereof |
| EP2575885A1 (en) | 2010-05-25 | 2013-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection |
| WO2013024157A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of host targeting agents for the treatment and the prevention of hcv infection |
| WO2013024158A1 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
| WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
| WO2013024156A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
| WO2014033266A1 (en) | 2012-08-31 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection |
| JP6393875B2 (ja) * | 2013-02-28 | 2018-09-26 | 公益財団法人ヒューマンサイエンス振興財団 | 抗体 |
| EP2778126A1 (en) | 2013-03-15 | 2014-09-17 | Clariant International Ltd. | Lithium transition metal phosphate secondary agglomerates and process for its manufacture |
| WO2014179716A2 (en) * | 2013-05-03 | 2014-11-06 | Emmetrope Ophthalmics Llc | IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECs) |
| JP2016525558A (ja) * | 2013-08-02 | 2016-08-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 結腸直腸ガンの処置に使用するための抗クローディン1抗体 |
| EP3027648A1 (en) * | 2013-08-02 | 2016-06-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-claudin 1 antibodies and uses thereof |
| US10746738B2 (en) * | 2015-02-27 | 2020-08-18 | The Regents Of The University Of Michigan | Claudin-1 peptide reagents and methods |
| EP3070103A1 (en) * | 2015-03-19 | 2016-09-21 | Institut Hospitalier Universitaire De Strasbourg | Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma |
| CN114907483B (zh) * | 2016-03-22 | 2024-07-26 | 国家医疗保健研究所 | 人源化抗claudin-1抗体及其用途 |
| US11170872B2 (en) | 2019-11-05 | 2021-11-09 | Apeel Technology, Inc. | Prediction of latent infection in plant products |
| EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
| EP4433042A4 (en) * | 2021-11-18 | 2025-10-15 | Univ Nebraska | NOVEL CLAUDIN-1 INHIBITORS FOR THERAPEUTIC INTERVENTION |
| US20250179170A1 (en) | 2022-03-08 | 2025-06-05 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| EP4532550A1 (en) | 2022-06-01 | 2025-04-09 | Alentis Therapeutics AG | Use of anti-claudin-1 antibodies to treat cholangiocarcinoma |
| CN120076826A (zh) | 2022-06-01 | 2025-05-30 | 阿伦蒂斯治疗股份公司 | 抗紧密连接蛋白-1抗体治疗胆管病的用途 |
| CN115850502A (zh) * | 2022-07-14 | 2023-03-28 | 清华-伯克利深圳学院筹备办公室 | 蛋白酶响应的gpcr受体及其应用 |
| JP2025533015A (ja) | 2022-09-30 | 2025-10-03 | アレンティス セラピューティクス アクチェンゲゼルシャフト | 薬物抵抗性肝細胞癌の処置 |
| CN121605309A (zh) | 2023-03-23 | 2026-03-03 | 阿伦蒂斯治疗股份公司 | 使用抗紧密连接蛋白-1抗体的癌症治疗的生物标志物 |
| WO2025224337A1 (en) | 2024-04-26 | 2025-10-30 | Alentis Therapeutics Ag | Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof |
| WO2025224335A1 (en) | 2024-04-26 | 2025-10-30 | Alentis Therapeutics Ag | Anti-cldn1 antibody-drug conjugates comprising mmae and methods of use thereof |
| WO2026057702A1 (en) | 2024-09-12 | 2026-03-19 | Alentis Therapeutics Ag | Claudin-1/egfr bispecific antibodies |
| WO2026057723A1 (en) | 2024-09-12 | 2026-03-19 | Alentis Therapeutics Ag | Claudin-1/egfr bispecific antibodies for targeted degradation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044384C (zh) * | 1994-08-25 | 1999-07-28 | 中国药品生物制品检定所 | 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体 |
| CN1089802C (zh) * | 1998-07-31 | 2002-08-28 | 中国药品生物制品检定所 | 抗丙型肝炎病毒非结构区4抗原的单克隆抗体细胞株及其单克隆抗体 |
| EP1167387A1 (en) | 2000-06-23 | 2002-01-02 | F. Hoffmann-La Roche Ag | Antibodies against SEMP1, methods for their production and uses thereof |
| AU750296B2 (en) * | 2000-06-23 | 2002-07-11 | F. Hoffmann-La Roche Ag | Antibodies against SEMP1, methods for their production and uses thereof |
| AU2007248493B2 (en) * | 2006-05-04 | 2010-09-30 | The Rockefeller University | HCV coreceptor and methods of use thereof |
-
2009
- 2009-09-25 ES ES09783424.6T patent/ES2529511T3/es active Active
- 2009-09-25 WO PCT/EP2009/062449 patent/WO2010034812A1/en not_active Ceased
- 2009-09-25 CA CA2738027A patent/CA2738027C/en active Active
- 2009-09-25 US US13/119,233 patent/US8518408B2/en active Active
- 2009-09-25 BR BRPI0919065-1A patent/BRPI0919065B1/pt active IP Right Grant
- 2009-09-25 JP JP2011528342A patent/JP5698137B2/ja active Active
- 2009-09-25 CN CN200980147935.XA patent/CN102224171B/zh active Active
- 2009-09-25 EP EP09783424.6A patent/EP2328933B1/en active Active
- 2009-09-25 KR KR1020117009324A patent/KR101698015B1/ko active Active
-
2011
- 2011-03-22 ZA ZA2011/02112A patent/ZA201102112B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010034812A1 (en) | 2010-04-01 |
| JP2012503632A (ja) | 2012-02-09 |
| CA2738027C (en) | 2018-12-04 |
| KR20110061634A (ko) | 2011-06-09 |
| US20110236347A1 (en) | 2011-09-29 |
| ZA201102112B (en) | 2012-07-25 |
| CA2738027A1 (en) | 2010-04-01 |
| CN102224171A (zh) | 2011-10-19 |
| US8518408B2 (en) | 2013-08-27 |
| JP5698137B2 (ja) | 2015-04-08 |
| CN102224171B (zh) | 2015-03-11 |
| ES2529511T3 (es) | 2015-02-20 |
| KR101698015B1 (ko) | 2017-01-19 |
| BRPI0919065B1 (pt) | 2021-09-21 |
| EP2328933A1 (en) | 2011-06-08 |
| EP2328933B1 (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919065A2 (pt) | anticorpos monoclonais anti-claudin-1 para a inibição de infecção por virus de hepatite c | |
| CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| IL205795A0 (en) | Hepatitis c virus antibodies | |
| IL209499A0 (en) | Monoclonal antibodies having homosubtype cross - neutralization properties against influenza a viruses subtype h1 | |
| PT2274335E (pt) | Anticorpos monoclonais capazes de reagirem com diversos subtipos de vírus a da gripe | |
| BRPI0919250A2 (pt) | métodos para a purificação de vírus | |
| CY2015012I1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| ATE555109T1 (de) | Hepatitis-c-virus-hemmer | |
| DK2066695T3 (da) | Anti-myostatin-antistoffer | |
| CY2015004I1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| IL239023A0 (en) | Neutralizing antibodies to influenza viruses | |
| DK2044121T3 (da) | Glyco-konstruerede antistoffer | |
| BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
| SMT201700083B (it) | Anticorpi monoclonali | |
| BRPI1010506A2 (pt) | "inibidores do vírus da hepatite c" | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| EP2331125A4 (en) | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS | |
| BRPI0907733A2 (pt) | Inibidores do vírus da hepatite c | |
| BRPI0809600A2 (pt) | vírus atenuado útil para vacinas | |
| CR20170001A (es) | Anticuerpos anti factor d humanizados | |
| BRPI0819210A2 (pt) | Anticorpos de proteína g anti-rsv | |
| EP2337798A4 (en) | SPECIFIC ANTIBODIES OF THE ASB | |
| BRPI0814111A2 (pt) | Anticorpo monoclonal citotóxico anticâncer | |
| DK3339865T3 (da) | Assay for jc-virus-antistoffer | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |